A validated integrated clinical and molecular glioblastoma long-term survival-predictive nomogram.
Neuroncol Adv 2021; 3(1):1-10
Background: Glioblastoma (GBM) is the most common primary malignant brain tumor in adulthood. Despite multimodality treatments, including maximal safe resection followed by irradiation and chemotherapy, the median overall survival times range from 14 to 16 months. However, a small subset of GBM patients live beyond 5 years and are thus considered long-term survivors.
Methods: A retrospective analysis of the clinical, radiographic, and molecular features of patients with newly diagnosed primary GBM who underwent treatment at The University of Texas MD Anderson Cancer Center was conducted. Eighty patients had sufficient quantity and quality of tissue available for next-generation sequencing and immunohistochemical analysis. Factors associated with survival time were identified using proportional odds ordinal regression. We constructed a survival-predictive nomogram using a forward stepwise model that we subsequently validated using The Cancer Genome Atlas.
Results: Univariate analysis revealed 3 pivotal genetic alterations associated with GBM survival: both high tumor mutational burden (
Conclusions: Our newly devised long-term survival
de Groot J,
A validated integrated clinical and molecular glioblastoma long-term survival-predictive nomogram. Neuroncol Adv 2021; 3(1):1-10
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License.